Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety Evaluation of IBI308 Versus Paclitaxel/Irinotecan in Patients With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment: a Randomized, Open-label, Multicenter, Phase 2 Study (ORIENT-2)

Next Previous
Trial Profile

Efficacy and Safety Evaluation of IBI308 Versus Paclitaxel/Irinotecan in Patients With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment: a Randomized, Open-label, Multicenter, Phase 2 Study (ORIENT-2)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sintilimab (Primary) ; Irinotecan; Paclitaxel
  • Indications Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms ORIENT-2
  • Sponsors Cinda Biopharmaceutical; Innovent Biologics

Most Recent Events

  • 15 Nov 2021 Results (N=1683) of meta-analysis and systematic review evaluating the efficacy and safety of PD-1 inhibitors monotherapy versus chemotherapy in second-line treatment of AEC published in the Clinical Therapeutics
  • 31 May 2020 Results evaluating the efficacy and safety of sintilimab in patients with advanced esophageal squamous cell carcinoma, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
  • 31 May 2020 According to an Innovent Biologics media release, results (as of 2nd Aug 2019) from this study were presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) (Abstract # 4511, Poster # 119, Friday, 29th May, 2020).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top